World's First Esophageal Cancer Virus Drug Launches in Japan

Japan has introduced Telomelysin, the world's first oncolytic virus drug approved for treating esophageal cancer, marking a breakthrough in cancer therapeutics. Developed by Oncolys BioPharma, a spin-off from Okayama University, and distributed by Fujifilm Toyama Chemical, the drug was officially launched in Japan on August 21, 2026. Telomelysin utilizes a genetically modified adenovirus—the same virus that causes common cold symptoms—to selectively target and destroy cancer cells from within, without harming healthy tissue. Each treatment course requires three injections directly administered into esophageal tumors via endoscope, priced at approximately 9.3 million yen (about HK$500,000). Under Japan's public health insurance and high-cost medical expense system, average salary earners with annual incomes between 3.7 million and 7.7 million yen pay roughly 170,000 yen (approximately HK$9,000) out of pocket. The therapy causes minimal side effects, primarily fever, offering a gentler alternative for elderly patients or those unsuitable for surgery or standard chemotherapy.

Telomelysin represents a paradigm shift in cancer treatment, establishing oncolytic virus therapy as the fifth pillar alongside surgery, radiation, chemotherapy, and immunotherapy. For Hong Kong patients, this breakthrough could eventually expand treatment options if the therapy receives approval or adoption regionally, particularly for elderly patients or those with organ dysfunction who cannot tolerate conventional treatments. The drug's successful development signals growing potential for similar targeted virus-based therapies against other cancer types worldwide.